R&D | January 14, 2026
Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
Subscribe To Our Newsletter & Stay Updated
